225 related articles for article (PubMed ID: 29979821)
1. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.
Adcock DM; Strandberg K; Shima M; Marlar RA
Int J Lab Hematol; 2018 Dec; 40(6):621-629. PubMed ID: 29979821
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
Marlar RA; Strandberg K; Shima M; Adcock DM
Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
[TBL] [Abstract][Full Text] [Related]
3. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
Kitchen S; Signer-Romero K; Key NS
Haemophilia; 2015 Jul; 21(4):550-7. PubMed ID: 25688866
[TBL] [Abstract][Full Text] [Related]
4. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
[TBL] [Abstract][Full Text] [Related]
5. One-stage vs. chromogenic assays in haemophilia A.
Potgieter JJ; Damgaard M; Hillarp A
Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
[TBL] [Abstract][Full Text] [Related]
6. Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B.
Kihlberg K; Strandberg K; Rosén S; Ljung R; Astermark J
Haemophilia; 2017 Jul; 23(4):620-627. PubMed ID: 28440032
[TBL] [Abstract][Full Text] [Related]
7. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
[TBL] [Abstract][Full Text] [Related]
8. Performance evaluation of Revohem
Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
[TBL] [Abstract][Full Text] [Related]
9. Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.
Miller CH
Haemophilia; 2018 Mar; 24(2):186-197. PubMed ID: 29446525
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
11. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of modified factor VIII and IX products.
Kitchen S; Gray E; Mertens K
Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
[TBL] [Abstract][Full Text] [Related]
13. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
Sommer JM; Buyue Y; Bardan S; Peters RT; Jiang H; Kamphaus GD; Gray E; Pierce GF
Thromb Haemost; 2014 Nov; 112(5):932-40. PubMed ID: 25144892
[TBL] [Abstract][Full Text] [Related]
14. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
Kitchen S; Kershaw G; Tiefenbacher S
Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
[TBL] [Abstract][Full Text] [Related]
16. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
[TBL] [Abstract][Full Text] [Related]
17. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
[TBL] [Abstract][Full Text] [Related]
18. The rapid Bethesda assay is equivalent to the standard Bethesda assay for detection of factor IX inhibitors in patients with severe haemophilia B.
Sahud M; Zhukov O; Naides SJ; Serrano C; Wong E; Dlott J; Racke F
Haemophilia; 2020 Jul; 26(4):735-740. PubMed ID: 32420682
[TBL] [Abstract][Full Text] [Related]
19. Role of chromogenic assays in haemophilia A and B diagnosis.
Bowyer AE; Duncan EM; Antovic JP
Haemophilia; 2018 Jul; 24(4):578-583. PubMed ID: 29808946
[TBL] [Abstract][Full Text] [Related]
20. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]